AUTHORS: Mainta I. C., Sfakianaki I., Shiri I., Botsikas D., Garibotto V.

Magnetic Resonance Imaging Clinics of North America, 31(4): 565-577, 7 August 2023

ABSTRACT

For T stage, dedicated-breast 18F-fluorodeoxyglucose (18F-FDG) PET/MR imaging is superior to whole-body acquisition with the MR imaging component being prominent for the diagnosis. For N stage, the high sensitivity of 18F-FDG PET/MR imaging can be combined with the high specificity of axillary ultrasound. For M stage, whole-body 18F-FDG PET/MR imaging has high diagnostic performance, with reduced radiation dose compared with 18F-FDG PET/computed tomography (CT). PET-metabolic and MR imaging-pharmacokinetic parameters, associated to histopathological characteristics of breast cancer, bear a predictive potential as proven on a research level, which could be further improved through radiomics and artificial intelligence. 18F-FDG PET/MR imaging can lead in change in treatment management in 14% to 33% of patients compared with conventional staging with mammography, ultrasound, and MR imaging and in 12% compared with 18F-FDG PET/CT.

BibTex

https://doi.org/10.1016/j.mric.2023.06.007

Module: